On November 17, 2026 Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, reported U.S. Food and Drug Administration clearance to proceed for the Investigational New Drug (IND) application to evaluate EIK1006 for the treatment of advanced metastatic prostate cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Eikon plans to initiate a Phase 1/2 study, ARGATE-001, to evaluate the safety, tolerability and preliminary efficacy of EIK1006 in participants with metastatic androgen-pathway-modulation-resistant prostate cancer (mAPMRPC) that has progressed on established anti-hormonal therapy. Formerly known as metastatic castration-resistant prostate cancer (mCRPC), mAPMRPC remains an area of high unmet need because resistance to established anti-hormonal therapy is common and limits durable benefit. EIK1006 is intended to address resistance driven by androgen receptor (AR) pathway alterations, including AR amplification and ligand-binding domain mutations. Eikon expects to begin dosing participants in this study in 2027, with preliminary safety and efficacy data to be available in the second half of 2027.
"IND clearance for EIK1006 is an important milestone for Eikon and for patients with advanced metastatic prostate cancer, where resistance to current androgen receptor-directed therapies remains a significant challenge. EIK1006’s progression into the clinic reflects the strength of our proprietary drug discovery platform and our ability to nominate novel chemical material and rapidly advance them into human studies," said Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon. "We look forward to initiating clinical evaluation of EIK1006 and to continuing to translate our platform into potential new medicines for patients with significant unmet need."
About EIK1006
EIK1006 is an internally-derived clinical candidate and is being investigated as a potential next-generation androgen receptor (AR) antagonist with activity against wild type and multiple clinically important genetic variants of AR that emerge during treatment with conventional AR antagonists. Preclinically, Eikon scientists have shown that EIK1006 binds to the ligand binding domain of AR and blocks its nuclear translocation, thereby inhibiting AR transcriptional activity and downstream signaling.
(Press release, Eikon Therapeutics, NOV 17, 2026, View Source [SID1234674844])